Scancell Holdings, the British developer of novel immunotherapies for the treatment of cancer, entered into an agreement with the University of Nottingham (UK) to acquire a number of novel monoclonal antibodies to tumour-associated glycans (Assigned Antibodies).
Alongside this, Scancell has also acquired a proprietary technology to enable the modification of the constant region (FC) of a human antibody to allow direct tumour killing.
Together these offer a complementary platform to Scancell’s existing cancer immunotherapy platforms, ImmunoBody® and Moditope®.
Advances in understanding the pattern of sugars (glycans) that adorn cells have highlighted important differences between those on tumour cells versus their normal counterparts. This altered sugar signature of tumour cells is intricately linked to the majority of cancer cell biology hallmarks. Antibodies that target such tumour glycan signatures, when coupled to a novel approach to invoke an immune response on binding, provide an attractive strategy for immunotherapy and forms the basis of the platform technology developed by Prof. Lindy Durrantand her team at the Nottingham University Therapeutic Antibody Centre (NUTAC).
Scancell will be responsible for the management, prosecution and maintenance of any patent applications assigned from the University of Nottingham to Scancell, as well as for the filing of new patent applications for the Assigned Antibodies. Under the terms of the agreement, the University of Nottingham is eligible to receive royalties on futurelicence revenue or net sales arising from the Assigned Antibodies